PharmaTher Holdings Ltd. (PHRRF)
| Previous Close | 0.0848 |
| Open | 0.0900 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0800 - 0.0900 |
| 52 Week Range | 0.0800 - 0.5910 |
| Volume | |
| Avg. Volume | 135,033 |
| Market Cap | 7.751M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0410 |
| Earnings Date | Oct 27, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson's Disease and Movement Disorders®
Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003), 49% at 3-week (p=0.006) and 41% at 3-month (p=0.011) post-ketaminePlanning a Phase 3 clinical study to allow for FDA approval of KETARX™ (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE
- GlobeNewswire
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
Figure 1 Figure 1: Actual prototype of KETARX™ Ketamine Patch Figure 2 Blood levels of ketamine delivery with KETARX™ ketamine patch relative to time with either a 5 cm2 or 10 cm2 patch KETARX™ Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARX™ Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better align with intramuscular and intravenous administration Initiating clinical studies by the end of Q4-2022 to suppor
- GlobeNewswire
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders
TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced today that the United States Patent and Trademark Office (“USPTO”) has provided a Notice of Allowance for patent application No. 15/574,346, titled “Compositions and Methods for Treating Motor Disorders”, which includes claims intended to cover ketamine in the potential treatment of Parkinson’s Disease and motor
